PLUS THERAPEUTICS, INC.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
2(a): Unregistered Sales of Equity Securities and Use of Proceeds
None.
2(b): Use of Proceeds from Registered Securities
None.
2(c): Purchases of Equity Securities
The following table provides certain information with respect to the Company's purchases of its common stock for the three months ended March 31, 2026.
| Company Purchases of Common Stock | ||||||
|---|---|---|---|---|---|---|
| Period · Total Number of Shares Purchased · Average Price Paid per Share · Total Number of Shares Purchased As Part of Publicly Announced Plans or Programs · Approximate Dollar Value of Shares That May Yet Be Purchased Under Plans or Programs(1) | ||||||
| January 1 - 31, 2026 | 272,821 | $16.50 | 272,821 | $ | - | |
| February 1 - 28, 2026 | - | $ | - | - | $ | - |
| March 1 - 31, 2026 | - | $ | - | - | $ | - |
| Total | 272,821 | $ | - | 272,821 | $ | - |
(1)
On March 4, 2025, the Company entered into the March 2025 SPA with the March 2025 Private Placement Purchasers for the March 2025 Private Placement . On June 17, 2025, the Company and the Purchasers entered into the Letter Agreement with each of the Purchasers in an effort to, among other items, minimize the dilutive impact of the March 2025 Private Placement and provided for the return and cancellation of Private Placement Shares and Pre-Funded Warrants. The Private Placement Shares and Pre-Funded Warrants were repurchased by the Company pursuant to the Letter Agreement. Refer to Note 12 Stockholders’ Equityin Part I, Item 1 of this Quarterly Report on Form 10-Q for more information on the Letter Agreement.
Item 5. Other Information
On May 12, 2026, the Company filed a Certificate of Correction (the “Certificate of Correction”) to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company (the “Certificate of Amendment”) that was previously filed on April 1, 2026. The Certificate of Amendment erroneously stated the number of authorized shares of common stock, par value $0.001 per share, of the Company (“Common Stock”) as 200,000,000 (two hundred million).
As corrected by the Certificate of Correction, the total number of authorized shares of Common Stock is two billion (2,000,000,000).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.